Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib
The DOI matches its Crossref record.
Abstract
Background: MONALEESA-7 (NCT02278120), the first large randomized phase III clinical trial dedicated to investigating a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus ET vs ET + placebo (PBO) in pre- or perimenopausal patients with HR+/HER2− ABC, previously demonstrated a statistically significant improvement in OS with the addition of ribociclib (RIB) to ET vs PBO + ET (median, not reached vs 40.9 months; HR, 0.71 [95% CI, 0.54-0.95]; P = .00973; Im SA, et al. N Engl J Med. 2019). This concluded the protocol-defined final analysis of OS and the patients and investigators were unblinded to their treatment assignment allowing patients on the PBO arm to cross-over to RIB treatment. Longer follow-up allows for more events to further characterize the long-term survival benefits. Here we report an exploratory update of OS after a minimum of ~ four years of follow-up, an additional 20 months since the last report. Methods: Pre- or perimenopausal patients with HR+/HER2− ABC were randomized 1:1 to receive RIB or PBO plus goserelin with either a nonsteroidal aromatase inhibitor (NSAI; letrozole or anastrozole) or tamoxifen. RIB is approved in combination with an NSAI in pre- or perimenopausal patients. Patients who had received a prior CDK4/6i or ET in the advanced setting were excluded. Patients who received ET in the (neo)adjuvant setting or ≤ 1 prior line of chemotherapy for advanced disease were eligible to enroll. Updated OS were evaluated by Cox proportional hazards model and summarized using Kaplan-Meier methods. Additional post-progression endpoints such as progression-free survival 2 (PFS2), time to chemotherapy (CT) and CT-free survival were also evaluated and summarized. Results: The data cutoff for this updated OS analysis was 29 June 2020, and the median follow-up was 53.5 mo (min, 46.9 mo). These updated results with extended follow-up demonstrated an OS benefit with RIB + ET vs PBO + ET (median, 58.7 vs 48.0 mo; HR, 0.76 [95% CI, 0.61-0.96]). In patients receiving an NSAI, a similar OS benefit was observed with RIB + NSAI vs PBO + NSAI (median, 58.7 vs 47.7 mo; HR, 0.80 [95% CI, 0.62-1.04]). The survival benefit shown in subgroup analyses was consistent with the intent-to-treat (ITT) population. PFS2, time to chemotherapy (CT), and CT-free survival for the ITT and NSAI populations are in the Table. Among the patients who discontinued study treatment, 77.3% and 78.1% in the RIB + ET vs PBO + ET arms received a subsequent antineoplastic therapy, respectively, and 12.9% and 26.1% received a subsequent line of CDK4/6i. Additionally there were 15 patients in the PBO arm that crossed over to the RIB arm following unblinding and prior to disease progression. Conclusions: With an extended follow-up of more than 4 years, RIB + ET continued to demonstrate a clinically relevant OS benefit compared with ET alone in pre- or perimenopausal patients with a median OS ~5 years with RIB +ET in HR+/HER2− ABC. A similar benefit with RIB was observed for PFS2, time to CT, and CT-free survival. ITTNSAI cohortRIB + ETn=335PBO + ETn=337RIB + NSAIn=248PBO + NSAIn=247PFS2Events, n (%)177 (52.8)221 (65.6)131 (52.8)159 (64.4)Median, mo44.231.043.630.4HR (95% CI)0.68 (0.56-0.83)0.69 (0.55-0.87)Time to first CTEvents, n (%)144 (43.0)173 (51.3)107 (43.1)129 (52.2)Median, mo50.936.850.936.0ITT HR(95% CI)0.69 (0.56-0.87)0.66 (0.51-0.85)CT-free survivalEvents, n (%)190 (56.7)236 (70.0)139 (56.0)169 (68.4)Median, mo42.426.442.525.9HR (95% CI)0.67 (0.55-0.81)0.64 (0.51-0.81) Citation Format: Debu Tripathy, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kümmel, Nagi El-Saghir, Mei-Ching Liu, Sharonjeet Kaur, Claudia Gasch, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yen-Shen Lu. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD2-04.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as well as impressive median survival to date (63.9 months) among women with HR-positive, HER2-negative advanced breast cancer. 16,20,22-29”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [22]
In the citing paper
“This trial has a long follow-up (median, 80 months). 19-23”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [22]
Citations
Cites
Still being checked.
Cited by
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2114663 · Cited by 791
Self-citationHuppert, L. A., Gumusay, O., Idossa, D., & Rugo, H. S. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 164
CDK inhibitors from past to present: A new wave of cancer therapy
Jameel, M., Bhadresha, K. P., & Kwok, H. F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.006 · Cited by 120
Nabieva, N., & Fasching, P. A. (2021) · Cancers · doi:10.3390/cancers13225643 · Cited by 46
Neven, P., Rugo, H. S., Tolaney, S. M., Iwata, H., Toi, M., Goetz, M. P., Kaufman, P. A., Lu, Y., Haddad, N., Hurt, K. C., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01463-2 · Cited by 39
Self-citation
Metadata
- Authors
- Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S., Chow, L., Sohn, J., Lee, K. S., Campos-Gomez, S., Vazquez, R. V., Jung, K. H., Babu, K. G., Wheatley-Price, P., De Laurentiis, M., Im, Y.-H., Kümmel, S., El-Saghir, N., Liu, M.-C., Kaur, S., Gasch, C., Wang, C., Wang, Y., Chakravartty, A., & Lu, Y.-S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Seoul National University (KR)
- European Institute of Oncology (IT)
- 4Hospital de Caridade de Ijuí, CACON, Ijuí, Brazil
- Harvard University (US)
- Ludwig-Maximilians-Universität München (DE)
- University of California, Los Angeles (US)
- 8Organisation for Oncology and Translational Research, Hong Kong, China
- Severance Hospital (KR)
- National Cancer Center (KR)
- 11Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico
- 12Institut Català d’Oncologia, Hospital Moisès Broggi, Barcelona, Spain
- Asan Medical Center (KR)
- Kidwai Memorial Institute of Oncology (IN)
- 15University of Ottawa, Ottawa, ON, Canada
- 16Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy
- Samsung Medical Center (KR)
- Kliniken Essen-Mitte (DE)
- American University of Beirut Medical Center (LB)
- Koo Foundation Sun Yat-Sen Cancer Center (TW)
- Novartis (India) (IN)
- 22Novartis Ireland Limited, Dublin, Ireland
- Novartis (Switzerland) (CH)
- 24Novartis Pharmaceuticals Corporation, East Hanover, NJ;
- National Taiwan University Hospital (TW)
- ORCID
- Venue
- Cancer Research
- Published
- 2021-02-15
- Volume
- 81
- Issue
- 4_Supplement
- Pages
- PD2-04-PD2-04
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W3132700492
- Cited by
- 30
- References
- 0
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 5 · 2022: 13 · 2021: 4
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- HR+/HER2- advanced breast cancer, ribociclib, CDK4/6 inhibitors, endocrine therapy, goserelin, overall survival, time to chemotherapy, long-term survival, aromatase inhibitors, tamoxifen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. https://app.cochat.ai/papers/10.1158/1538-7445.sabcs20-pd2-04
- The paper
- Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S., Chow, L., Sohn, J., Lee, K. S., Campos-Gomez, S., Vazquez, R. V., Jung, K. H., Babu, K. G., Wheatley-Price, P., De Laurentiis, M., Im, Y.-H., Kümmel, S., El-Saghir, N., . . . Lu, Y.-S. (2021). Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Cancer Research. https://doi.org/10.1158/1538-7445.sabcs20-pd2-04
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.